论文部分内容阅读
目的研究低分子肝素钙治疗重症肺心病并心力衰竭的临床疗效。方法回顾性分析入我院治疗的56例重症肺心病并心力衰竭患者的临床资料,随机分为治疗组和对照组各28例,两组患者均给予常规治疗,治疗组在此基础上加用低分子肝素钠进行治疗,比较两组患者的临床疗效和治疗前后气体分压情况。结果疗程结束后,治疗组的总有效率为89.29%,显著高于对照组的78.56%,P<0.05;治疗前两组患者的动脉血PO2和PCO2均无显著性差异,治疗后治疗组的动脉血PO2高于对照组,PCO2显著低于对照组,P<0.05。结论重症肺心病并心力衰竭患者在常规治疗的基础上加用低分子肝素钠进行治疗,能显著提高动脉血PO2,降低PCO2,临床疗效显著。
Objective To study the clinical effect of low molecular weight heparin calcium in patients with severe pulmonary heart disease and heart failure. Methods The clinical data of 56 patients with severe pulmonary heart disease and heart failure treated in our hospital were retrospectively analyzed. They were randomly divided into treatment group (n = 28) and control group (n = 28). Both groups were given conventional treatment. On the basis of this, Low molecular weight heparin for treatment, the clinical efficacy of two groups were compared and before and after treatment gas partial pressure situation. Results After the treatment, the total effective rate of the treatment group was 89.29%, which was significantly higher than that of the control group (78.56%, P <0.05). There was no significant difference of PO2 and PCO2 between the two groups before treatment PO2 in arterial blood was higher than that in control group, PCO2 was significantly lower than that in control group, P <0.05. Conclusions Severe pulmonary heart disease and heart failure patients treated with low molecular weight heparin on the basis of routine treatment can significantly improve arterial blood PO2 and reduce PCO2, with a significant clinical effect.